{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T21:53:19Z","timestamp":1787003599076,"version":"build-2736575974"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,7,23]],"date-time":"2024-07-23T00:00:00Z","timestamp":1721692800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,7,23]],"date-time":"2024-07-23T00:00:00Z","timestamp":1721692800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>We conducted a retrospective population-based, matched cohort study using the National Health Insurance Research Database to estimate healthcare resource utilisation (HRU) and costs in patients with newly diagnosed AL amyloidosis in Taiwan. Cases were matched 10:1 by age, sex, and area of residence to patients without AL amyloidosis (comparators) randomly selected from the database during the same time period. Annual all-cause HRU and costs for 3\u00a0years were quantified. AL amyloidosis-attributable costs were obtained by subtracting all-cause HRU costs incurred by comparators from cases. The mean age of all patients was 60.78\u00a0years and 59.07% were male. Co-morbidities were more frequent in cases than comparators. By 6\u00a0months after diagnosis, 12.1% of cases had died versus 0.9% of comparators. In the first year, cases had 103% more outpatient visits, 177% more emergency room visits, were hospitalised 4-times more frequently, and spent 5.5-times more days in hospital than comparators, and total healthcare costs were\u2009&gt;\u2009sixfold higher. Costs incurred during the first year after diagnosis accounted for 55% of the 3-year cumulative cost. High HRU costs associated with delayed diagnosis and end-organ damage indicate a need for earlier diagnosis and more effective treatments for AL amyloidosis.<\/jats:p>","DOI":"10.1038\/s41598-024-65654-5","type":"journal-article","created":{"date-parts":[[2024,7,23]],"date-time":"2024-07-23T13:02:28Z","timestamp":1721739748000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Healthcare resource utilisation and costs associated with AL amyloidosis: a retrospective matched cohort study"],"prefix":"10.1038","volume":"14","author":[{"given":"Shih-Pei","family":"Shen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hsin-An","family":"Hou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kuan-Chih","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Choo Hua","family":"Goh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong","family":"Qiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lee Anne","family":"Rothwell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kwang-Wei","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hitesh","family":"Chandwani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanfang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chao-Hsiun","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,7,23]]},"reference":[{"key":"65654_CR1","first-page":"470","volume":"10","author":"YL Hwa","year":"2019","unstructured":"Hwa, Y. L. et al. Immunoglobulin light-chain amyloidosis: Clinical presentations and diagnostic approach. J. Adv. Pract. Oncol. 10, 470\u2013481 (2019).","journal-title":"J. Adv. Pract. Oncol."},{"key":"65654_CR2","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1111\/ejh.13679","volume":"107","author":"LL Hester","year":"2021","unstructured":"Hester, L. L. et al. Diagnostic delay and characterization of the clinical prodrome in AL amyloidosis among 1523 US adults diagnosed between 2001 and 2019. Eur. J. Haematol. 107, 428\u2013435 (2021).","journal-title":"Eur. J. Haematol."},{"key":"65654_CR3","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1038\/s41408-021-00483-7","volume":"11","author":"M Hasib Sidiqi","year":"2021","unstructured":"Hasib Sidiqi, M. & Gertz, M. A. Immunoglobulin light chain amyloidosis diagnosis and treatment algorithm 2021. Blood Cancer J. 11, 90 (2021).","journal-title":"Blood Cancer J."},{"key":"65654_CR4","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1182\/hematology.2020006913","volume":"2020","author":"G Palladini","year":"2020","unstructured":"Palladini, G., Milani, P. & Merlini, G. Management of AL amyloidosis in 2020. Hematol. Am. Soc. Hematol. Educ. Program 2020, 363\u2013371 (2020).","journal-title":"Hematol. Am. Soc. Hematol. Educ. Program"},{"key":"65654_CR5","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1111\/bjh.16096","volume":"187","author":"E Muchtar","year":"2019","unstructured":"Muchtar, E. et al. Ten-year survivors in AL amyloidosis: Characteristics and treatment pattern. Br. J. Haematol. 187, 588\u2013594 (2019).","journal-title":"Br. J. Haematol."},{"key":"65654_CR6","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1016\/j.mayocp.2018.08.041","volume":"94","author":"RA Kyle","year":"2019","unstructured":"Kyle, R. A. et al. Incidence of AL amyloidosis in Olmsted County, Minnesota, 1990 through 2015. Mayo Clin. Proc. 94, 465\u2013471 (2019).","journal-title":"Mayo Clin. Proc."},{"key":"65654_CR7","doi-asserted-by":"publisher","first-page":"15736","DOI":"10.1038\/s41598-022-18990-3","volume":"12","author":"HA Hou","year":"2022","unstructured":"Hou, H. A. et al. A population-based cohort study of the epidemiology of light-chain amyloidosis in Taiwan. Sci. Rep. 12, 15736 (2022).","journal-title":"Sci. Rep."},{"key":"65654_CR8","doi-asserted-by":"publisher","first-page":"3741","DOI":"10.1200\/JCO.2015.62.4015","volume":"33","author":"A D'Souza","year":"2015","unstructured":"D\u2019Souza, A. et al. Improved outcomes after autologous hematopoietic cell transplantation for light chain amyloidosis: A center for international blood and marrow transplant research study. J. Clin. Oncol. 33, 3741\u20133749 (2015).","journal-title":"J. Clin. Oncol."},{"key":"65654_CR9","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1159\/000507072","volume":"143","author":"P Milani","year":"2020","unstructured":"Milani, P. & Palladini, G. Conventional therapy for amyloid light-chain amyloidosis. Acta Haematol. 143, 365\u2013372 (2020).","journal-title":"Acta Haematol."},{"key":"65654_CR10","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1159\/000508287","volume":"143","author":"T Dittrich","year":"2020","unstructured":"Dittrich, T., Kimmich, C., Hegenbart, U. & Schonland, S. O. Prognosis and staging of AL amyloidosis. Acta Haematol. 143, 388\u2013400 (2020).","journal-title":"Acta Haematol."},{"key":"65654_CR11","doi-asserted-by":"publisher","first-page":"1017","DOI":"10.1080\/03007995.2017.1297930","volume":"33","author":"HM Lin","year":"2017","unstructured":"Lin, H. M. et al. Disease burden of systemic light-chain amyloidosis: A systematic literature review. Curr. Med. Res. Opin. 33, 1017\u20131031 (2017).","journal-title":"Curr. Med. Res. Opin."},{"key":"65654_CR12","doi-asserted-by":"publisher","first-page":"1046","DOI":"10.1182\/bloodadvances.2018016402","volume":"2","author":"TP Quock","year":"2018","unstructured":"Quock, T. P., Yan, T., Chang, E., Guthrie, S. & Broder, M. S. Epidemiology of AL amyloidosis: A real-world study using US claims data. Blood Adv. 2, 1046\u20131053 (2018).","journal-title":"Blood Adv."},{"key":"65654_CR13","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/13506129.2017.1411796","volume":"25","author":"P Hari","year":"2018","unstructured":"Hari, P. et al. Treatment patterns and health care resource utilization among patients with relapsed\/refractory systemic light chain amyloidosis. Amyloid 25, 1\u20137 (2018).","journal-title":"Amyloid"},{"key":"65654_CR14","unstructured":"National Health Insurance Annual Statistical Report 2020. National Health Insurance Administration, Ministry of Health and Welfare, Republic of China, December 31, 2021."},{"key":"65654_CR15","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1111\/j.1532-5415.2011.03868.x","volume":"60","author":"K Dharmarajan","year":"2012","unstructured":"Dharmarajan, K. & Maurer, M. S. Transthyretin cardiac amyloidoses in older North Americans. J. Am. Geriatr. Soc. 60, 765\u2013774 (2012).","journal-title":"J. Am. Geriatr. Soc."},{"key":"65654_CR16","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1093\/qjmed\/91.2.141","volume":"91","author":"SW Dubrey","year":"1998","unstructured":"Dubrey, S. W. et al. The clinical features of immunoglobulin light-chain (AL) amyloidosis with heart involvement. QJM 91, 141\u2013157 (1998).","journal-title":"QJM"},{"key":"65654_CR17","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1002\/ajh.20381","volume":"79","author":"MA Gertz","year":"2005","unstructured":"Gertz, M. A. et al. Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): A consensus opinion from the 10th International Symposium on Amyloid and Amyloidosis, Tours, France, 18\u201322 April 2004. Am. J. Hematol. 79, 319\u2013328 (2005).","journal-title":"Am. J. Hematol."},{"key":"65654_CR18","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1016\/S1665-2681(19)30916-0","volume":"13","author":"B Norero","year":"2013","unstructured":"Norero, B. et al. Portal hypertension and acute liver failure as uncommon manifestations of primary amyloidosis. Ann. Hepatol. 13, 142\u2013149 (2013).","journal-title":"Ann. Hepatol."},{"key":"65654_CR19","doi-asserted-by":"publisher","first-page":"1460","DOI":"10.1093\/ndt\/gfy291","volume":"34","author":"R Rysava","year":"2019","unstructured":"Rysava, R. AL amyloidosis: Advances in diagnostics and treatment. Nephrol. Dial Transplant. 34, 1460\u20131466 (2019).","journal-title":"Nephrol. Dial Transplant."},{"key":"65654_CR20","first-page":"121","volume":"4","author":"JL Rubin","year":"2011","unstructured":"Rubin, J. L. et al. Epidemiology, survival, and costs of localized gastrointestinal stromal tumors. Int. J. Gen. Med. 4, 121\u2013130 (2011).","journal-title":"Int. J. Gen. Med."},{"key":"65654_CR21","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1186\/1471-2407-11-250","volume":"11","author":"M Vera-Llonch","year":"2011","unstructured":"Vera-Llonch, M. et al. Healthcare costs in women with metastatic breast cancer receiving chemotherapy as their principal treatment modality. BMC Cancer 11, 250 (2011).","journal-title":"BMC Cancer"},{"key":"65654_CR22","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1016\/j.lungcan.2015.09.005","volume":"90","author":"L Schwarzkopf","year":"2015","unstructured":"Schwarzkopf, L. et al. Cost-components of lung cancer care within the first three years after initial diagnosis in context of different treatment regimens. Lung Cancer 90, 274\u2013280 (2015).","journal-title":"Lung Cancer"},{"key":"65654_CR23","doi-asserted-by":"crossref","unstructured":"Cheng, H. M., et al. Real-world cost-effectiveness of drug-eluting stents versus bare-metal stents for coronary heart disease\u2014A five-year follow-up study. Health Policy 123, 229\u2013234 (2019).","DOI":"10.1016\/j.healthpol.2018.11.010"},{"key":"65654_CR24","doi-asserted-by":"publisher","first-page":"12","DOI":"10.4065\/mcp.2010.0480","volume":"86","author":"SK Kumar","year":"2011","unstructured":"Kumar, S. K. et al. Recent improvements in survival in primary systemic amyloidosis and the importance of an early mortality risk score. Mayo Clin Proc. 86, 12\u201318 (2011).","journal-title":"Mayo Clin Proc."},{"key":"65654_CR25","doi-asserted-by":"publisher","first-page":"549","DOI":"10.2217\/cer-2017-0100","volume":"7","author":"TP Quock","year":"2018","unstructured":"Quock, T. P., Yan, T., Chang, E., Guthrie, S. & Broder, M. S. Healthcare resource utilization and costs in amyloid light-chain amyloidosis: A real-world study using US claims data. J. Comp. Eff. Res. 7, 549\u2013559 (2018).","journal-title":"J. Comp. Eff. Res."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-65654-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-65654-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-65654-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,23]],"date-time":"2024-07-23T13:06:37Z","timestamp":1721739997000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-65654-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,23]]},"references-count":25,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["65654"],"URL":"https:\/\/doi.org\/10.1038\/s41598-024-65654-5","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,23]]},"assertion":[{"value":"15 July 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 June 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 July 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"KCH, CHG, LAR, HQ, KWW, HC and YL are employees of Janssen Research & Development LLC or Janssen Asia\u2013Pacific. HC, HQ, LAR, and YL hold stock in Johnson & Johnson. SPS, HSH and CHT declare no conflicts of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"16915"}}